AI Revolutionizes Pharma: Eli Lilly's $2.75B Deal with Insilico Medicine

• Eli Lilly partners with Insilico Medicine in a $2.75 billion deal to accelerate AI-developed drug discovery and development.
• The collaboration aims to make drug research faster, more effective, and could significantly reduce development timelines from years to months.
• Insilico Medicine, a Hong Kong-based company, has already developed 28 drugs using generative AI, with half reaching clinical trials.
• This partnership strengthens an existing collaboration and integrates Insilico into Lilly's Gateway Labs network for biotech innovation.
• The deal signals a shift in the pharmaceutical industry, urging Indian companies to invest in AI and R&D to remain competitive; 8 Indian stocks identified for potential impact.